981 related articles for article (PubMed ID: 15125740)
1. Occult metastases in axillary lymph nodes as a predictor of survival in node-negative breast carcinoma with long-term follow-up.
Reed W; Bøhler PJ; Sandstad B; Nesland JM
Breast J; 2004; 10(3):174-80. PubMed ID: 15125740
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
[TBL] [Abstract][Full Text] [Related]
3. Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system.
Kahn HJ; Hanna WM; Chapman JA; Trudeau ME; Lickley HL; Mobbs BG; Murray D; Pritchard KI; Sawka CA; McCready DR; Marks A
Breast J; 2006; 12(4):294-301. PubMed ID: 16848838
[TBL] [Abstract][Full Text] [Related]
4. The prognostic importance of immunohistochemically detected node metastases in resected esophageal adenocarcinoma.
Waterman TA; Hagen JA; Peters JH; DeMeester SR; Taylor CR; Demeester TR
Ann Thorac Surg; 2004 Oct; 78(4):1161-9; discussion 1161-9. PubMed ID: 15464464
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of occult metastases and isolated tumor cells in sentinel and non-sentinel lymph nodes in early breast cancer patients: serial step section analysis with long-term follow-up.
Takeshita T; Tsuda H; Moriya T; Yamasaki T; Asakawa H; Ueda S; Sato K; Aida S; Tamai S; Matsubara O; Hase K; Yamamoto J
Ann Surg Oncol; 2012 Apr; 19(4):1160-6. PubMed ID: 21989659
[TBL] [Abstract][Full Text] [Related]
6. Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma: A preliminary study.
Dowlatshahi K; Fan M; Bloom KJ; Spitz DJ; Patel S; Snider HC
Cancer; 1999 Sep; 86(6):990-6. PubMed ID: 10491525
[TBL] [Abstract][Full Text] [Related]
7. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study.
Weaver DL; Krag DN; Ashikaga T; Harlow SP; O'Connell M
Cancer; 2000 Mar; 88(5):1099-107. PubMed ID: 10699901
[TBL] [Abstract][Full Text] [Related]
8. Early distant relapse in "node-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour.
Colpaert C; Vermeulen P; Jeuris W; van Beest P; Goovaerts G; Weyler J; Van Dam P; Dirix L; Van Marck E
J Pathol; 2001 Apr; 193(4):442-9. PubMed ID: 11276002
[TBL] [Abstract][Full Text] [Related]
9. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis.
Torrenga H; Fabry H; van der Sijp JR; van Diest PJ; Pijpers R; Meijer S
J Surg Oncol; 2004 Oct; 88(1):4-7; discussion 7-8. PubMed ID: 15384064
[TBL] [Abstract][Full Text] [Related]
10. The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast.
Broekhuizen LN; Wijsman JH; Peterse JL; Rutgers EJ
Eur J Surg Oncol; 2006 Jun; 32(5):502-6. PubMed ID: 16569492
[TBL] [Abstract][Full Text] [Related]
11. Sentinel lymph node biopsy alone has no adverse impact on the survival of patients with breast cancer.
Takei H; Suemasu K; Kurosumi M; Horii Y; Ninomiya J; Yoshida M; Hagiwara Y; Inoue K; Tabei T
Breast J; 2006; 12(5 Suppl 2):S157-64. PubMed ID: 16958996
[TBL] [Abstract][Full Text] [Related]
12. Histological detection of minimal metastatic involvement in axillary sentinel nodes: a rational basis for a sensitive methodology usable in daily practice.
Fréneaux P; Nos C; Vincent-Salomon A; Genin P; Sigal-Zafrani B; Al Ghuzlan A; Birolini MJ; Clough K; Sastre-Garau X
Mod Pathol; 2002 Jun; 15(6):641-6. PubMed ID: 12065778
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry.
Chagpar A; Middleton LP; Sahin AA; Meric-Bernstam F; Kuerer HM; Feig BW; Ross MI; Ames FC; Singletary SE; Buchholz TA; Valero V; Hunt KK
Cancer; 2005 Apr; 103(8):1581-6. PubMed ID: 15747375
[TBL] [Abstract][Full Text] [Related]
14. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of occult nodal metastasis in early breast carcinoma.
Park D; Kåresen R; Naume B; Synnestvedt M; Beraki E; Sauer T
Breast Cancer Res Treat; 2009 Nov; 118(1):57-66. PubMed ID: 19219629
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of lymph node metastases in node-negative breast cancer patients.
Kohlberger P; Gantert M; Volk-Orlowska T; Kieback DG; Gitsch G
Anticancer Res; 2001; 21(1B):697-9. PubMed ID: 11299828
[TBL] [Abstract][Full Text] [Related]
17. Micrometastases in axillary lymph nodes and bone marrow of lymph node-negative breast cancer patients--prognostic relevance after 10 years.
Gebauer G; Fehm T; Merkle E; Jaeger W; Mitze M
Anticancer Res; 2003; 23(5b):4319-24. PubMed ID: 14666645
[TBL] [Abstract][Full Text] [Related]
18. [Value of cancer-related oncoprotein expression as prognostic factors in breast-cancer with one to three axillary lymph nodes positive].
Zhang G; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S
Gan To Kagaku Ryoho; 1996 Mar; 23 Suppl 1():66-74. PubMed ID: 8702314
[TBL] [Abstract][Full Text] [Related]
19. [Axillary skip metastases in breast cancer].
Sun JY; Ning LS
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):352-5. PubMed ID: 18953834
[TBL] [Abstract][Full Text] [Related]
20. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
